Jury upholds three Repatha patent claims

A jury upheld the validity of three of the five asserted claims covering two U.S. patents for PCSK9 inhibitor Repatha evolocumab from Amgen

Read the full 235 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE